Parkinson DiseaseNMDATNCT02650843
Non-motor Symptoms and Brain Dopamine Transporter Binding
An observational study of Parkinson Disease and Parkinsonism, run by Turku University Hospital.
Trial summary
This project aims to clarify the role non-motor symptoms in the development of Parkinson's disease (PD) and to improve diagnostics at very early stages of PD. The project involves multidimensional measures of disease biomarkers together with brain dopamine transporter (DAT) imaging with [123I]FP-CIT single photon… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Parkinson Disease, Parkinsonism
- What is being tested?
- DAT SPECT imaging
- How many people
- 455 participants
- Where
- No sites listed yet
- Study dates
- Jan 2015to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with parkinsonism
Who may be able to join
- Male or Female
- Age 18-100 years
- Referred for clinical DAT SPECT in Turku or Helsinki
Who cannot join
None listed.
About this study
Official title: Non-motor Symptoms and Brain Dopamine Transporter Binding: An Observational Study in Parkinsonism
This project aims to clarify the role non-motor symptoms in the development of Parkinson's disease (PD) and to improve diagnostics at very early stages of PD. The project involves multidimensional measures of disease biomarkers together with brain dopamine transporter (DAT) imaging with [123I]FP-CIT single photon emission computed tomography (SPECT).
- Conditions
- Parkinson Disease, Parkinsonism
- Being tested
- DAT SPECT imaging
- Keywords
- Parkinsonism, DAT Dopamine transporter, SPECT
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DAT SPECT imagingOther
| Study group | Role | What they receive |
|---|---|---|
| Patients with parkinsonism | Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland Receives: Other: DAT SPECT imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
DAT SPECT striatal specific binding ratio
Measured: Up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2016 (estimated)
- Study startJan 2015
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Turku University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 455 participants (actual)
Sponsor and investigators
- Lead sponsor
- Turku University Hospital
- Sponsor type
- Other government
- Collaborators
- Helsinki University Central Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02650843
- Sponsor's protocol ID
- T12/2014
- Acronym
- NMDAT
- Status last verified
- Apr 2025
- First submitted
- 5 Jan 2016
- Last updated
- 13 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Vahlberg T, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic value of micrographia in Parkinson's disease: a study with [123I]FP-CIT SPECT. J Neural Transm (Vienna). 2022 Jul;129(7):895-904. doi: 10.1007/s00702-022-02517-1. Epub 2022 May 27.
PubMed 35624405Nuuttila S, Eklund M, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic accuracy of glabellar tap sign for Parkinson's disease. J Neural Transm (Vienna). 2021 Nov;128(11):1655-1661. doi: 10.1007/s00702-021-02391-3. Epub 2021 Jul 30.
PubMed 34328563
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-motor Symptoms and Brain Dopamine Transporter Binding: An Observational Study in Parkinsonism
- ClinicalTrials.gov ID
- NCT02650843
- Acronym / sponsor ID
- NMDAT / T12/2014
- Conditions
- Parkinson Disease, Parkinsonism
- Keywords
- Parkinsonism, DAT Dopamine transporter, SPECT
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 455 participants (actual)
- Lead sponsor
- Turku University HospitalOther government
- Collaborators
- Helsinki University Central Hospital
- Study start
- Jan 2015
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 8 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project aims to clarify the role non-motor symptoms in the development of Parkinson's disease (PD) and to improve diagnostics at very early stages of PD. The project involves multidimensional measures of disease biomarkers together with brain dopamine transporter (DAT) imaging with [123I]FP-CIT single photon emission computed tomography (SPECT).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with parkinsonism | – | Other: DAT SPECT imagingPatients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with parkinsonism
Key inclusion criteria (3 listed)
- Male or Female
- Age 18-100 years
- Referred for clinical DAT SPECT in Turku or Helsinki
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DAT SPECT imaging | Other | Patients with parkinsonism |
Primary outcome
DAT SPECT striatal specific binding ratio
Time frame: Up to 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2025.
- Derived from this study: PubMed 35624405Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Vahlberg T, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic value of micrographia in Parkinson's disease: a study with [123I]FP-CIT SPECT. J Neural Transm (Vienna). 2022 Jul;129(7):895-904. doi: 10.1007/s00702-022-02517-1. Epub 2022 May 27.
- Derived from this study: PubMed 34328563Nuuttila S, Eklund M, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, Lindholm K, Noponen T, Ihalainen T, Murtomaki K, Nojonen T, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V. Diagnostic accuracy of glabellar tap sign for Parkinson's disease. J Neural Transm (Vienna). 2021 Nov;128(11):1655-1661. doi: 10.1007/s00702-021-02391-3. Epub 2021 Jul 30.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson Disease
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
Recruiting
Effects of Microelectrode-based Brain Stimulation in Humans
Essential Tremor, Parkinsons Disease (PD)
Not yet recruitingPhase 1
Stanford University Neurofiber Study
PARKINSON DISEASE (Disorder)
Recruiting
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
Healthy Individuals (Controls), Parkinson Disease
Not yet recruiting
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
Idiopathic Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease and Parkinsonism, run by Turku University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DAT SPECT striatal specific binding ratio (time frame: Up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02650843, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2025.